ArriVent Biopharma
18 Campus Blvd.
Suite 100
Newtown Square
PA
19073
United States
15 articles about ArriVent Biopharma
-
ArriVent BioPharma Reports Full Year 2023 Financial Results
3/28/2024
ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the full year ended December 31, 2023, and highlighted recent company progress.
-
Late Thursday, ArriVent Biopharma announced its upsized initial public offering to support the development of its EGFR inhibitor furmonertinib, following CG Oncology going public earlier in the day.
-
ArriVent Announces Pricing of Upsized Initial Public Offering - Jan 26, 2024
1/26/2024
ArriVent BioPharma, Inc. announced the pricing of its upsized initial public offering of 9,722,222 shares of its common stock at a public offering price of $18.00 per share.
-
With initial public offering activity continuing to gain momentum in early 2024, ArriVent Biopharma in a Monday SEC filing laid out the company’s plans to go public.
-
The IPO window is starting to crack open this year, with Metagenomi and ArriVent making their offerings ahead of the J.P. Morgan Healthcare Conference.
-
ArriVent Appoints Winston Kung as Chief Financial Officer and Treasurer
1/5/2024
ArriVent Biopharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, announced the appointment of Winston Kung as Chief Financial Officer and Treasurer.
-
ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
10/30/2023
ArriVent Biopharma, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for furmonertinib for the treatment of patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
-
Allist and ArriVent Announce Interim Results from Ongoing Phase 1b Trial with Furmonertinib at the 2023 World Conference on Lung Cancer
9/10/2023
Allist Pharmaceuticals Co., Ltd. and ArriVent Biopharma, Inc. together announced that interim results from the Phase Ib, randomized, open-label, multi-center clinical study, evaluating the efficacy and safety of furmonertinib in patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
-
InnoCare and ArriVent Announce Clinical Development Collaboratio
7/14/2023
InnoCare Pharma and ArriVent Biopharma announced a clinical development collaboration to evaluate the combination of InnoCare’s novel SHP2 allosteric inhibitor, ICP-189, with ArriVent’s furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor.
-
Despite a tough financing market, ArriVent Biopharma closed a $155 million Series B to fund a pivotal Phase III trial of its non-small cell lung cancer asset.
-
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
3/27/2023
ArriVent Biopharma, Inc. today announced the completion of a $155 million oversubscribed Series B financing.
-
ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors
2/15/2022
ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment of Bahija Jallal, Ph.D. to its Board of Directors.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform
12/23/2021
Aarvik Therapeutics and ArriVent Biopharma Inc. today announced a strategic research collaboration to develop and commercialize an undisclosed oncology-focused drug candidate.
-
The new funding will be used to advance the company’s potential best-in-class epidermal growth factor receptor tyrosine kinase inhibitor furmonertinib, a lung cancer treatment that has been licensed from Allist Pharmaceuticals.